<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="207">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733807</url>
  </required_header>
  <id_info>
    <org_study_id>Max-2821</org_study_id>
    <nct_id>NCT04733807</nct_id>
  </id_info>
  <brief_title>Antibodies Response to mRNA Vaccine Against Covid-19</brief_title>
  <acronym>SABREVAC</acronym>
  <official_title>SARS-Cov-2 Antibodies Response to BNT162b2 mRNA Vaccine to Prevent Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICOT University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the&#xD;
      moment is the mRNA-based BNT162b2 and is given to Hospital employers. The investigators&#xD;
      undertake this study to monitor IgM and IgG evolution after vaccination in the participant&#xD;
      hospital settings, which includes 500 subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the&#xD;
      moment is the mRNA-based BNT162b2 and is given to Hospital employers.&#xD;
&#xD;
      The investigators undertake this observational study to monitor antibody evolution after&#xD;
      vaccination in a hospital setting. The primary endpoint is serum IgM and IgG at the first&#xD;
      month of 2nd jab, and at 3, 6, and 12 months afterward.&#xD;
&#xD;
      As secondary measures, nasopharyngeal swabs are included, at fortnight intervals to detects&#xD;
      the spike protein antigen, in the event that putative vaccine inefficacy would expose the&#xD;
      health personnel to Covid-19 disease with potential spreading to inpatients.&#xD;
&#xD;
      Further, clinical signs and symptoms are monitored at the weekly interval in the context of&#xD;
      adverse reactions/events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum IgM and IgG antibodies levels in response to vaccine</measure>
    <time_frame>Serum antibody at 1 months</time_frame>
    <description>Determination of IgM and IgG levels in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum IgM and IgG antibodies levels in response to vaccine</measure>
    <time_frame>Serum antibody at 3 months</time_frame>
    <description>Determination of IgM and IgG levels in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum IgM and IgG antibodies levels in response to vaccine</measure>
    <time_frame>Serum antibody at 6 months</time_frame>
    <description>Determination of IgM and IgG levels in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum IgM and IgG antibodies levels in response to vaccine</measure>
    <time_frame>Serum antibody at 12 months</time_frame>
    <description>Determination of IgM and IgG levels in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sars-Cov2 infection in vaccinated subjects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Monitoring of Sars-Cov2 infection by a nasopharyngeal swab of spike protein Ag, and PCR confirmation in case of Ag swab positivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covid-19 disease in vaccinated subjects</measure>
    <time_frame>Clinical monitoring of vaccinated subjects through the study completion, an average of 1 year.</time_frame>
    <description>Monitoring the occurrence of Covid-19 disease in vaccinated people</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid-19</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2 mRNA Covid-19 Vaccine</intervention_name>
    <description>Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Health care and administrative workers of ICOT-Sapienza University Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospital employers vaccinated against Sars-Cov2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Iuliano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lugi Iuliano, M.D.</last_name>
    <phone>+393406462332</phone>
    <email>luigi.iuliano@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Polidoro, M.D.</last_name>
    <phone>+393478115718</phone>
    <email>alessandro.polidoro@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICOT-Sapienza University Hospital</name>
      <address>
        <city>Latina</city>
        <state>LT</state>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lugi Iuliano, M.D.</last_name>
      <phone>+393406462332</phone>
      <email>luigi.iuliano@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Alessandro Polidoro, M.D.</last_name>
      <phone>+393478115718</phone>
      <email>alessandro.polidoro@uniroma1.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Luigi Iuliano</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>Covid-19</keyword>
  <keyword>safety</keyword>
  <keyword>Sars-Cov2</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

